Q2 EPS Forecast for Viridian Therapeutics Boosted by Analyst

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Investment analysts at HC Wainwright upped their Q2 2026 EPS estimates for Viridian Therapeutics in a research note issued to investors on Wednesday, May 6th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of ($1.14) for the quarter, up from their previous estimate of ($1.22). HC Wainwright currently has a "Buy" rating and a $22.00 target price on the stock. The consensus estimate for Viridian Therapeutics' current full-year earnings is ($3.73) per share. HC Wainwright also issued estimates for Viridian Therapeutics' Q3 2026 earnings at ($1.09) EPS, Q4 2026 earnings at ($1.14) EPS, FY2026 earnings at ($4.28) EPS, FY2027 earnings at ($3.20) EPS, FY2028 earnings at ($2.59) EPS, FY2029 earnings at ($1.04) EPS and FY2030 earnings at $0.90 EPS.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.16. Viridian Therapeutics had a negative net margin of 490.31% and a negative return on equity of 80.19%. The business had revenue of $0.14 million during the quarter, compared to analyst estimates of $0.04 million. During the same quarter last year, the firm posted ($0.87) earnings per share. The business's revenue for the quarter was up 95.8% compared to the same quarter last year.

Other analysts have also recently issued research reports about the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $32.00 target price on shares of Viridian Therapeutics in a report on Tuesday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Viridian Therapeutics in a report on Monday, April 20th. Truist Financial reduced their target price on shares of Viridian Therapeutics from $36.00 to $33.00 and set a "buy" rating on the stock in a report on Tuesday, April 21st. Wells Fargo & Company reduced their target price on shares of Viridian Therapeutics from $29.00 to $20.00 and set an "equal weight" rating on the stock in a report on Tuesday, March 31st. Finally, The Goldman Sachs Group cut their price objective on shares of Viridian Therapeutics from $36.00 to $31.00 and set a "buy" rating on the stock in a report on Tuesday, April 7th. Twelve analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $37.31.

Viridian Therapeutics Trading Down 3.0%

NASDAQ VRDN opened at $17.00 on Friday. The firm has a 50 day simple moving average of $21.57 and a 200-day simple moving average of $26.94. The firm has a market cap of $1.75 billion, a price-to-earnings ratio of -5.12 and a beta of 0.82. Viridian Therapeutics has a one year low of $11.98 and a one year high of $34.29. The company has a debt-to-equity ratio of 0.10, a quick ratio of 12.65 and a current ratio of 15.15.

Hedge Funds Weigh In On Viridian Therapeutics

Hedge funds have recently modified their holdings of the business. ANTIPODES PARTNERS Ltd purchased a new position in shares of Viridian Therapeutics during the fourth quarter worth approximately $36,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Viridian Therapeutics during the third quarter worth approximately $35,000. KBC Group NV purchased a new position in shares of Viridian Therapeutics during the first quarter worth approximately $34,000. Farther Finance Advisors LLC grew its position in shares of Viridian Therapeutics by 332.1% during the third quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company's stock worth $42,000 after acquiring an additional 1,491 shares during the last quarter. Finally, Bessemer Group Inc. grew its position in shares of Viridian Therapeutics by 947.7% during the third quarter. Bessemer Group Inc. now owns 2,085 shares of the company's stock worth $45,000 after acquiring an additional 1,886 shares during the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc NASDAQ: VRDN is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company's lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.